1054 related articles for article (PubMed ID: 26607440)
41. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
42. [THE EFFECT OF BIOLOGIC THERAPY ON THE LIPID PROFILE OF RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS) PATIENTS].
Hassan S; Feld J; Cohen S; Zisman D
Harefuah; 2017 Jul; 156(7):446-450. PubMed ID: 28786273
[TBL] [Abstract][Full Text] [Related]
43. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
44. Real-world retention rates of biologics in patients with rheumatoid arthritis.
Takami K; Tsuji S
Sci Rep; 2023 Dec; 13(1):21170. PubMed ID: 38040839
[TBL] [Abstract][Full Text] [Related]
45. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
46. Biologic efficacy optimization--a step towards personalized medicine.
Kiely PD
Rheumatology (Oxford); 2016 May; 55(5):780-8. PubMed ID: 26424837
[TBL] [Abstract][Full Text] [Related]
47. Adverse effects of TNF inhibitors in SpA: are they different from RA?
Sampaio-Barros PD; van der Horst-Bruinsma IE
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):747-63. PubMed ID: 25488782
[TBL] [Abstract][Full Text] [Related]
48. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
[TBL] [Abstract][Full Text] [Related]
49. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases.
Mok CC; van der Kleij D; Wolbink GJ
Clin Rheumatol; 2013 Oct; 32(10):1429-35. PubMed ID: 23887439
[TBL] [Abstract][Full Text] [Related]
50. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
51. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Simpson EL; Ren S; Hock ES; Stevens JW; Binard A; Pers YM; Archer R; Paisley S; Stevenson MD; Herpin C; Ghabri S
Int J Technol Assess Health Care; 2019 Jan; 35(1):36-44. PubMed ID: 30722803
[TBL] [Abstract][Full Text] [Related]
52. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
[TBL] [Abstract][Full Text] [Related]
53. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
[TBL] [Abstract][Full Text] [Related]
54. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
55. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
56. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.
Reddy SM; Crean S; Martin AL; Burns MD; Palmer JB
Clin Rheumatol; 2016 Dec; 35(12):2955-2966. PubMed ID: 27730309
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
Batticciotto A; Ravasio R; Riva M; Sarzi-Puttini P
Adv Ther; 2016 Aug; 33(8):1360-73. PubMed ID: 27376373
[TBL] [Abstract][Full Text] [Related]
58. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
59. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
60. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
